Profile data is unavailable for this security.
About the company
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.
- Revenue in USD (TTM)5.44m
- Net income in USD-14.10m
- Incorporated2006
- Employees11.00
- LocationKineta Inc7683 Se 27Th Street, Suite 481MERCER ISLAND 98040United StatesUSA
- Phone+1 (206) 378-0400
- Fax+1 (302) 636-5454
- Websitehttps://kinetabio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ainos Inc | 122.11k | -13.77m | 6.19m | 46.00 | -- | 0.199 | -- | 50.71 | -3.32 | -3.32 | 0.0298 | 5.23 | 0.0035 | 0.9854 | 1.21 | 2,654.57 | -39.94 | -36.36 | -42.28 | -58.33 | -207.80 | 36.82 | -11,277.18 | -813.63 | 1.72 | -91.59 | 0.1961 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
Palisade Bio Inc | 250.00k | -12.30m | 6.21m | 9.00 | -- | 0.3984 | -- | 24.83 | -28.22 | -28.22 | 0.5485 | 18.30 | 0.0168 | -- | 0.3153 | 27,777.78 | -82.51 | -132.36 | -101.58 | -165.45 | -- | -- | -4,920.00 | -27,892.32 | -- | -856.33 | 0.0138 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
TFF Pharmaceuticals Inc | 733.87k | -21.24m | 6.22m | 19.00 | -- | 0.6119 | -- | 8.48 | -12.67 | -12.67 | 0.4097 | 4.04 | 0.0406 | -- | 2.37 | 38,624.74 | -117.54 | -79.57 | -130.37 | -83.41 | -- | -- | -2,894.69 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
CV Sciences Inc | 16.00m | 3.10m | 6.31m | 42.00 | 1.87 | 2.15 | 1.89 | 0.3942 | 0.0206 | 0.0206 | 0.104 | 0.018 | 1.46 | 1.46 | 26.74 | 381,047.60 | 28.28 | -43.42 | 247.47 | -77.75 | 44.27 | 51.81 | 19.38 | -45.68 | 0.3733 | 13.68 | 0.0805 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
CeCors Inc | -100.00bn | -100.00bn | 6.31m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
Azitra Inc | 686.00k | -12.64m | 6.33m | 10.00 | -- | 0.9132 | -- | 9.23 | -2.99 | -2.99 | 0.0713 | 0.2408 | 0.1117 | -- | 4.88 | 68,600.00 | -183.73 | -- | -266.83 | -- | -- | -- | -1,644.87 | -- | -- | -45.86 | 0.0138 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
Kineta Inc | 5.44m | -14.10m | 6.37m | 11.00 | -- | 2.02 | -- | 1.17 | -1.43 | -1.43 | 0.5297 | 0.278 | 0.3927 | -- | -- | 494,727.30 | -101.57 | -66.16 | -318.39 | -86.61 | -- | -- | -258.65 | -854.74 | -- | -1,310.25 | 0.2011 | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
Sentient Brands Holdings Inc | 160.00 | -379.70k | 6.37m | 2.00 | -- | -- | -- | 39,829.26 | -0.007 | -0.007 | 0.00 | -0.0308 | 0.0006 | -0.0026 | -- | 80.00 | -149.74 | -224.47 | -- | -- | 462.50 | 41.35 | -237,312.50 | -27,393.23 | 0.0005 | -0.6995 | -- | -- | -16.18 | -- | -100.19 | -- | -- | -- |
Stemtech Corp | 4.64m | -4.08m | 6.37m | 45.00 | -- | -- | -- | 1.37 | -0.0624 | -0.0624 | 0.0619 | -0.0092 | 1.09 | 8.35 | 65.16 | 103,098.40 | -96.70 | -- | -- | -- | 76.09 | -- | -88.58 | -- | 0.1045 | -1.81 | 2.27 | -- | -- | -- | -- | -- | -- | -- |
Processa Pharmaceuticals Inc | 0.00 | -11.12m | 6.45m | 13.00 | -- | 0.5825 | -- | -- | -8.72 | -8.72 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -154.40 | -84.35 | -175.45 | -90.03 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
Lixte Biotechnology Holdings Inc | 0.00 | -5.09m | 6.48m | 3.00 | -- | 13.10 | -- | -- | -2.77 | -2.77 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -103.09 | -104.18 | -111.07 | -111.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
Scorpius Holdings Inc | 2.23m | -46.05m | 6.49m | 77.00 | -- | 0.1294 | -- | 2.91 | -1.78 | -2.00 | 0.0859 | 1.39 | 0.0234 | -- | 0.6762 | 28,918.57 | -50.05 | -38.42 | -61.25 | -42.06 | 29.10 | -- | -2,136.28 | -703.02 | -- | -- | 0.2305 | -- | 202.12 | 33.24 | -23.85 | -- | 218.50 | -- |
Cell MedX Corp | 70.00 | -96.91k | 6.54m | 0.00 | -- | -- | -- | 93,417.15 | -0.0029 | -0.0029 | 0.00 | -0.0024 | 0.0015 | -- | -- | -- | -202.28 | -792.55 | -- | -- | -685.71 | -- | -138,442.90 | -3,681.84 | -- | -3.17 | -- | -- | -54.53 | -- | 29.01 | -- | -- | -- |
Glucose Health Inc | 1.11m | -456.46k | 6.56m | 2.00 | -- | 6.92 | -- | 5.89 | -0.033 | -0.033 | 0.0803 | 0.0561 | -- | -- | -- | -- | -- | -86.94 | -- | -153.95 | 47.19 | 40.68 | -31.99 | -56.93 | 313.11 | -- | 0.00 | -- | 98.39 | 24.94 | 16.87 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 31 Dec 2023 | 825.79k | 7.53% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 151.38k | 1.38% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 123.72k | 1.13% |
Geode Capital Management LLCas of 31 Dec 2023 | 50.58k | 0.46% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 22.31k | 0.20% |
Financial Advocates Investment Management LLCas of 31 Dec 2023 | 21.74k | 0.20% |
Renaissance Technologies LLCas of 31 Dec 2023 | 19.04k | 0.17% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 18.85k | 0.17% |
Element Pointe Advisors LLCas of 31 Dec 2023 | 17.70k | 0.16% |
Northern Trust Global Investments Ltd.as of 31 Dec 2023 | 14.57k | 0.13% |